| Customization: | Available |
|---|---|
| CAS No.: | 135459-87-9 |
| Formula: | C12h6n2o8SSR2 |
|
Still deciding? Get samples of US$ 10/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Melting point | >310°C (dec.) |
| storage temp. | -20°C Freezer |
| solubility | H2O: soluble1mg/mL, clear (warmed) |
| form | powder |
| color | white to beige |
| CAS DataBase Reference | 135459-87-9 |
Strontium ranelate is a medicine for the treatment of osteoporosis. Its appearance is white to slightly yellow powder or crystalline powder. It is odorless, slightly soluble in water, almost insoluble in ethanol, and easily soluble in dilute hydrochloric acid. It is produced by the French company Servier Researched and developed, first listed in Ireland in November 2004 and listed in the UK in December of the same year.
Clinically, it is mainly used to treat and prevent osteoporosis in postmenopausal women, and significantly reduce the risk of vertebral fractures and hip fractures. Strontium ranelate has the dual pharmacological effects of inhibiting bone resorption and promoting bone formation. On the one hand, osteoblast-enriched cells can increase the synthesis of collagen and non-collagen, and promote osteoblast-mediated bone formation by enhancing the proliferation of pre-osteoblasts.
On the other hand, by reducing osteoclast differentiation and resorption activity, reducing bone resorption, so that bone renewal is rebalanced, which is beneficial to bone formation. Strontium ranelate exerts its pharmacological effects mainly through strontium atoms. Strontium is an alkaline earth metal element of the same family as calcium and is located below calcium in the periodic table. Its absorption, distribution, and excretion are similar to calcium. After oral administration of 2g Chemicalbook. The absolute bioavailability of strontium is 27%.
Large doses of strontium can cause abnormal bone mineral metabolism. Low doses of strontium can enhance the replication of pre-osteoblasts, increase the number of osteoblasts, and stimulate bone formation; at the same time, it can also reduce the activity of osteoclasts and reduce osteoclasts. Quantity, reduce the rate of bone resorption. The results obtained in animal and human studies are in agreement. Osteoporosis (OP) is a progressive bone disease characterized by decreased bone density (BMD) and degenerative changes in the microstructure of bone tissue. It is manifested by increased bone fragility and susceptibility to fractures, the latter being the most common in the spine, hips and wrists. After menopause or after undergoing surgery to remove the ovaries, women stop producing estrogen that can keep bones strong.
Therefore, primary OP is especially common in postmenopausal or menopausal women. Currently, there are two types of drugs commonly used to treat osteoporosis: one is drugs that inhibit the activity of osteoclasts to inhibit bone resorption, such as bisphosphonates, estrogen, calcitonin, etc.; the second is to promote osteoblasts For drugs that are active to stimulate bone formation, only human recombinant parathyroid hormone 1-34 is currently on the market, which requires injection and has a high drug price.
){kind=link}